HIVPediatrics
Meeting category
Date(s)
27 Jul 2022 - 28 Jul 2022
Location
Montréal, Canada
Meeting type
Hybrid Meeting
Organizer

International Workshop on HIV & Pediatrics 2022

Related Enduring Materials

Enduring Materials
Session 1: Global Update on Pediatric HIV -
2022 Update on the HIV Epidemic in Infants, Children, Adolescents, and Women
Mary Mahy, ScD, MHSc
UNAIDS, Switzerland
What’s on the Horizon Post-2021 Guidelines
Session 2: Pediatric Care and Treatment -
Innovations in Long-Acting New ARVS and Drug Formulations/Delivery Devices for Children
Keerti Gedela, FRCP, MSc, DTM&H
56 Dean Street, Chelsea & Westminster Hospital / Imperial College, United Kingdom
Potential for Pediatric HIV Cure: Clinical Research Update
Deborah Persaud, MD
Johns Hopkins University School of Medicine / Johns Hopkins Bloomberg School of Public Health, United States
Oral Abstract Presentations
#1 - First Pharmacokinetic Data of Dolutegravir in Combination With a TAF Containing Backbone in Children Living With HIV
Lisanne Bevers
Netherlands
#2 - One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Children ≥ 2 Years Weighing 14 to < 25kg
Carina A. Rodriguez
United States
#3 - Weight Changes After Initiation of an Integrase Strand Transfer Inhibitor Among Adolescents and Young Adults With Perinatal HIV in the United States: A Descriptive Cohort Study
Kunjal Patel
United States
#4 - The Fast and the Continuous: Dolutegravir-Based Antiretroviral Therapy Achieves Impressive Viral Load Suppression in CALHIV in the Short- and Long-Term
Jason Bacha
Tanzania
Challenges in Diagnosis and Treatment of Cancer in Children and Adolescents, Including Those Living with HIV, in Africa
Lorna Awo Renner, MBChB, MPH, FRCPCH, FGCPS
University of Ghana Medical School, Ghana
Global Alliance to End AIDS in Children by 2030 – Introducing a New Global Strategic Initiative
Chewe Luo, MD, PhD
UNICEF, United States
Meg Doherty, MD, PhD
WHO, Switzerland
Session 3: Comorbidities/Co-Infections -
Complexities and Successes in Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Adolescents in Haiti
Vanessa Rouzier, MD
GHESKIO Centers, Haiti and Weill Cornell Center for Global Health, Haiti
Oral Abstract Presentations
#5 - Age-Related Non-communicable Diseases and Organ System Impairment in Adolescents and Young Adults Living With Perinatal HIV in Thailand
Supattra Rungmaitree
Thailand
#6 - Incidence of SARS-CoV-2 Infection and Clinical Characteristics in Children and Young People Living With HIV in Europe
Elizabeth Chappell
United Kingdom
#7 - Hospitalisation Patterns Among Infants With HIV in the Era of Universal Antiretroviral Therapy in South Africa
Kim Anderson
South Africa
#8 - A Longitudinal Assessment of the Impact of Antiretroviral Therapy and HIV-1 Associated Inflammation on Neurocognitive Outcomes in Perinatally Infected (PHIV) Children in South Africa
Shalena Naidoo
South Africa
#9 - Subcortical Brain Volumes of Children Who Are HIV-Exposed and Uninfected in the First Three Years of Life: A South African Birth Cohort Study
Catherine Wedderburn
South Africa
Clinical Case Presentations with Panel -
Case Presentation 1
Sibongiseni Sanele Malinga, MBChB, Dip HIV Man (SA)
King Edward VII Hospital, South Africa
Case Presentation 2
Short Oral Poster Presentations
#21 - Optimizing ART for CALHIV by Shifting PI-based ART to Dolutegravir-Based ART Maintained and Achieved Viral Load Suppression
Jason Bacha, Tanzania
#22 - Transition to Dolutegravir (DTG)-based ART is Associated With Sex and Viral Load Access in a Prospective Cohort of West-African Children and Adolescents Living With HIV
Valériane Leroy, France
#23 - Expedited Development and Registration Resulting in Successful Uptake of Generic, Pediatric Dolutegravir Products for Low- And Middle-Income Countries Through an Innovative Public-Private Partnership
Margaret Louey, United States
#24 - Congenital Cytomegalovirus (cCMV) Infection Among Children Exposed to HIV in Utero in the CMIS Montréal Cohort
Fatima Kakkar, Canada
Day 2 - Thursday, 28 July 2022
Session 4: Prevention of New Pediatric HIV Infections (and Improving Maternal Health) -
Panel Discussion: Prevention of Vertical HIV Transmission and Ensuring Maternal Health in Sub-Saharan Africa in the Era of COVID-19: Challenges and Opportunities
Angela Mushavi, MBChB, MMed Pediatrics
Ministry of Health and Child Care, Zimbabwe
Aleny Couto, MD
Ministry of Health, Mozambique
Ameena Goga, MD, MS, PhD
SAMRC, South Africa
Oral Abstract Presentations
#10 - Cost-Effectiveness of Broadly Neutralizing Antibodies for HIV Prophylaxis for All Infants Born in High-Burden Settings
Christopher Alba
United States
#11 - Combination Adherence Support for HIV Pre-exposure Prophylaxis (PrEP) During Pregnancy in Malawi: A Pilot Randomized Trial
Friday Saidi
Malawi
#12 - Association of Prenatal Prep Exposure With Neurodevelopmental and Growth Outcomes Beyond 24 Months Among Kenyan Children
Lauren Gomez
United States
#13 - Mbereko+Men - Partners for PMTCT! Impact of a Gender-Synchronized Community-Based Intervention on Maternal Mental Health and Care-Seeking in Rural Zimbabwe
Karen Webb
Zimbabwe
#14 - Optimizing Diagnostic Technologies for Pediatric HIV– Function or Location? Modeling Analysis of Point-of-Care Technologies in Matabeleland South, Zimbabwe
Clare Flanagan
United States
#15 - Long-Term Risk of Hospitalization and Chronic Disease Among Children Who Were HIV Exposed and Uninfected (CHEU) Compared to Population Controls in Montreal, Canada
Fatima Kakkar
Canada
New Directions in Infant Postnatal Antiretroviral Prophylaxis and Treatment
Tim Cressey, MSc, PhD
Chiang Mai University, Thailand
Short Oral Poster Presentations
#25 - Low Birth Weight Among Infants Born to Women Living With HIV and HIV-Uninfected Women at CA-IeDEA Sites in Rwanda
Natalia Zotova, United States
#26 - Cognitive Functioning of Children HIV-Exposed, Uninfected: Preliminary Outcomes and Risk Factors
Julia Young, Canada
#27 - Association Between Caregivers Depression With Adherence and Viral Suppression Among HIV Infected Children Aged < 10 Years on Follow up at Kenyatta National Hospital in Kenya.
Agatha Kihiu, Kenya
#28 - The Impact of ART History Prior to Pregnancy on Postpartum Gaps in HIV Care Among Women Living With HIV in Khayelitsha, South Africa
Renee de Waal, South Africa
#29 - Changes in Bone Turnover Markers After Delivery in Breastfeeding Mothers With and Without ART
Kristin Baltrusaitis, United states
Session 5: Adolescents and Young Adults -
Debate: DTG Transition: A Switch to DTG Must be Accompanied by Change in NRTI Backbone in Children
Anna Turkova, MD
UCL / Great Ormond Street Hospital, United Kingdom
Eleanor Namusoke-Magongo, MD, MBChB, MMed
Ministry of Health, AIDS Control Program, Uganda
Oral Abstract Presentations
#16 - National Implementation of the Validated HIV Testing Eligibility Screening Tool and Expansion of Index Testing to Improve Identification of Children and Adolescents Living With HIV in Uganda in 2021
David Mabirizi
United States
#17 - Comparative HIV Risk Screening Tool (HRST) Performance of a Validated and Alternative Optimized HRSTs for Children and Adolescents in Uganda, Tanzania, and Malawi: A Pooled Analysis
Rhoderick Machekano
United States
#18 - Adding to the HIV Testing Services Toolkit! Caregiver-Assisted Oral HIV Screening of Children 18 Months – 14 Years in Uganda and Zambia
Carl Stecker
United States
#19 - Viral Load Coverage Among Children Living with HIV Under Five Years of Age in USAID-Supported Health Facilities in Eleven High-Burden Countries, 2019-2021
Kimberly Frost
United States
#20 - Reciprocal Relationships Between Beliefs About Condoms and Condomless Anal Sex Among YMSM Prescribed PrEP
Andrew Barnett
United States
15:45
Social Determinants of Health and HIV Infection in Youth in High and Low Resource Settings
Carmen Logie, MSW, PhD
Global Health Equity & Social Justice with Marginalized Populations / University of Toronto, Canada
Overview
Welcome
Group_Photo_HIV&Pediatrics2022

The 14th International Workshop on HIV & Pediatrics took place as a hybrid meeting from 27-28 July 2022 at Sofitel Montreal Golden Mile in Montreal, Canada. The workshop was attended by 290 attendees (185 in-person and 105 virtual attendees) from 39 countries.

The International Workshop on HIV & Pediatrics 2023 will take place from 21-22 July 2023 in Brisbane, Australia.

Although we have witnessed a dramatic global scale-up of antiretroviral treatment (ART) as well as efforts to prevent vertical HIV transmission in the last decade, there were 160,000 new pediatric infections in 2018 and an estimated 1.7 million children <15 years of age living with HIV. Children are substantially less likely than adults to be diagnosed, initiate treatment, and achieve durable viral suppression. Currently, only 54% are receiving ART, and treatment of pediatric HIV infection, particularly in infants and young children, remains complex and problematic, with continued use of suboptimal ART formulations and regimens.

Furthermore, adolescents are one of the most rapidly growing populations with HIV; in 2018, there were an estimated 510,000 new HIV infections among young people aged 15- 24 years, accounting for 30% of all new HIV infections globally. HIV infections among adolescent girls and young women are 60% higher than among adolescent boys and young men of the same age, with 6,000 new infections occurring in young women weekly. HIV remains one of the leading causes of death among adolescents living in Africa and among the top 10 causes of death in adolescents globally. The uptake of HIV testing among adolescents has remained low. Programs continue to struggle to reach and retain adolescents in care, and adherence to treatment has special challenges, particularly among those with perinatal infection aging up into adolescence and young adulthood.

As research to improve pediatric HIV diagnosis and care is ongoing, new scientific questions of critical importance have also emerged. In settings with mature ART programs, an increasing proportion of new pediatric infections is attributed to women acquiring HIV infection during pregnancy and breastfeeding, periods of markedly increased risk of HIV acquisition for the mother. With the scale-up of ART for PMTCT, the prevalence of pre-treatment antiretroviral (ARV) drug resistance, particularly to non-nucleoside reverse transcriptase inhibitor drugs, has escalated among newly diagnosed infants, jeopardizing ART effectiveness. Additionally, with more than 1.3 million pregnant women globally receiving ART, there are increasing concerns about the long-term impact of in utero and postnatal exposures to medications for those children who escape HIV.

Currently, the global population of HIV-exposed uninfected children and adolescents is estimated at 14.8 million, including over 8 million with in utero ARV exposure. Recent findings of an association with periconception dolutegravir exposure and increased risk of neural tube defects have underscored the need for ongoing attention to the safety of ARVs in pregnancy. Innovation in early infant diagnosis such as point of- care tests has facilitated earlier identification of HIV infection during infancy, providing exciting new opportunities to study acute infection and very early treatment in neonates and promising remission strategies. However, despite the critical importance of these topics, research in pediatric, adolescent, and maternal HIV infection is often neglected at major scientific HIV conferences.

Therefore, in collaboration with leading experts in the field, we have established a highly focused international workshop on the prevention and treatment of pediatric HIV infection. The overall objective of the International Workshop on HIV Pediatrics is to stimulate research that will advance prevention and treatment strategies for infants, children, and adolescents.

Local Co-Chairs 2022
Workshop Chairs
General Information 
Venue
This year's edition will take place at Sofitel Montreal Golden Mile.

Address:
1155 Sherbrooke Street West
Montreal, Quebec H3A 2N3
Canada
Unique Features
- Research in the prevention and treatment of HIV in pregnant/lactating women, infants, children, and adolescents will be discussed.

- A good representation of organizations involved in HIV treatment and care in HIV & Pediatrics.

- Special Session to address the most recent research.

- Early-career investigator awards for best oral presentation and best poster presentation.

- 6 dedicated poster walks.

- 28 (mini-) oral presentations.

- An extraordinary record of supporting scientific achievement as demonstrated in the success across the cascade from abstract presentation to publication.
Who Should Attend?
- Researchers

- Clinicians

- Nurses

- Industry specialists working in academic settings, hospitals, and non-governmental organizations (NGO)
Meeting Objectives
This meeting aims at:

- Enhancing communication and encouraging new collaborations between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote advances in HIV prevention and care in children, youth, and families.

- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through the posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.

- Providing updates on the latest research on new pediatric antiretroviral drugs and treatment and prevention strategies in children and adolescents.

- Evaluating the effectiveness of and gaps in programs for the prevention of perinatal HIV transmission and interventions to improve such programs.

- Sharing results from implementation science research on how to optimally implement proven interventions for the prevention of perinatal HIV transmission and pediatric and adolescent care and treatment in developing countries.

- Understanding complications of long-term HIV and its therapy, to enable improved management of HIV in children and adolescents.
Learning Objectives
After participating in this activity, participants will be able to:

- Describe the changing epidemiology of the pediatric HIV epidemic worldwide and the latest recommendations for pediatric and adolescent HIV treatment.

- Describe the impact of the COVID-19 pandemic on pediatric and maternal HIV programs and what we know about SARS-CoV-2 infection in African children.

- Summarize optimal treatment and management strategies of HIV infection in infants, children, adolescents, and pregnant and postpartum women.

- Describe potential complications of HIV and newer HIV treatments on children, adolescents, and pregnant/postpartum women.

- Summarize strategies to improve perinatal HIV prevention programs and to better understand the continued risk for perinatal transmission in the ART era.

- Describe special issues related to HIV in adolescents and young people and new HIV prevention modalities and programming options for youth.

- Understand new long-acting prevention technologies and their application for the prevention of HIV in adolescents.
Practical Information 
COVID-19 Entry Requirements
Due to the COVID-19 epidemic, a number of travel restrictions has been implemented. We ask you to read carefully the entry requirements below to find out if you are eligible to travel to Canada.

You are allowed to travel to Canada if:
- You qualify as fully vaccinated; *
- You have received at least two COVID-19 vaccine doses and the second was at least 14 days before your planned arrival to Canada (or one dose of the Janssen/Johnson & Johnson vaccine);
- You have no signs or symptoms of COVID-19;
- Your proof of vaccination is in English/French or you have a certified translation in English/French;
- You have your ArriveCAN receipts including your vaccination, contact and travel information;

*Accepted Vaccines are considered the following:
- AstraZeneca/COVISHIELD (ChAdOx1-S, Vaxzevria, AZD1222)
- Bharat Biotech (Covaxin, BBV152 A, B, C)
- Janssen/Johnson & Johnson – 1 dose
- Medicago Covifenz
- Moderna (Spikevax, mRNA-1273) including for children aged 6 to 11 years
- Novavax (NVX-COV2373, Nuvaxovid, Covovax)
- Pfizer-BioNTech (Comirnaty, tozinameran, BNT162b2) including for children aged 5 to 11 years
- Sinopharm BIBP (BBIBP-CorV)
- Sinovac (CoronaVac, PiCoVacc)

For more information, visit our COVID-19 tab.
VISA Application
If you are not a US citizen, you will need a visa or Electronic Travel Authorization (eTA) to travel to Canada.

To apply for a visitor VISA you will need to upload online the below documents:
- Proof of vaccination
- ArriveCAN receipt (electronic or paper)
- Identity document

To apply for an eTA you will need to complete an online form and submit the below documents:
- A valid passport from a visa-exempt country
- A valid email address

You can find more information here: https://www.cic.gc.ca/english/visit/visas.asp
Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the workshop and post-workshop survey.
Language
The official language of the workshop is English.
Translation will not be provided.
Enduring Materials
Enduring materials will be available here shortly after the conclusion of the workshop.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided that the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration

Registration is closed.

Fees and Conditions

Academia - Physical Participation

Academia -Virtual Participation

Industry - Physical/Virtual Participation

Early Fee (payment before/on 26 January 2022)

€395.00

€197.50

€1395.00

Regular Fee (payment before/on 26 May 2022)

€595.00

€297.50

€1695.00

Late Fee (payment before/on 26 July 2022)

€795.00

€397.50

€1795.00

Same Day Fee (payment from 27 to 28 July 2022)

€895.00

€447.50

€1895.00

Discounts

Early-Career Investigators / Academia from Resource-Limited Settings (RLS)* WITH an accepted abstract

Fee Waived

Early-Career Investigators / Academia from Resource-Limited Settings (RLS)* WITHOUT an accepted abstract

50% Off Current Academia Fee

Academia from high-income countries WITH ACCEPTED ABSTRACT

Early Academia fee

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

50% Off Current Academia Fee

Members of Endorsers

25% Off Current Academia Fee

Sponsors

Contact Secretariat

If eligible for a discount, please contact the workshop secretariat via christina.moustakaki@amededu.com for the special registration code.

*Countries included in the low-income and middle-income economies list of the World Bank Classification

**If you have financial concerns, please contact the workshop secretariat.

Important
  • We strongly advise that you register early to ensure that your registration is secured.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

Registration Fee Includes
- Access to all scientific sessions, including poster area

- Virtual Workshop pack, including abstract book and program

IMPORTANT:

- Payment can only be made by credit card.

- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For registration of groups larger than 5 participants, please contact Christina Moustakaki at Christina.Moustakaki@amededu.com to use the Group Registration Portal.
Academia from Resource-Limited Settings (RLS) / Early-Career Investigators
We are pleased to waive the registration fee for academia from low-income and lower-middle-income countries and early-career investigators with an accepted abstract. Additionally, a 50% discount on the registration fee will be provided for those without an accepted abstract. The application form is available below.

IMPORTANT: The registration fee is waived for the presenting author only.

To be eligible as an early-career investigator, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
Sponsored Attendance
If you are invited by a pharmaceutical or diagnostic company, or if your registration is organized by a travel agency, please do not register online. The sponsoring company will be asked to register you via the workshop secretariat.
Payment
By credit card only: online or by written authorization.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 16 June 2022: 50% refund (minus an administration fee of €40)

- Cancellation after 16 June 2022: Unfortunately, no refund will be given

If you are unable to attend the workshop, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 20 June 2022. A statement (email/letter) of cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the workshop, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the workshop, the workshop secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previously written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop

A free or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the workshop secretariat for registration conditions.

We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2021 embargo policy.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Abstracts

The Abstract Submission Portal is now closed.

Abstract Submission Deadline: 29 April 2022 at 23:59 EDT
Categories for Abstract Submission
For purposes of review and programming, abstracts are divided into topical categories. The selection of the most appropriate category is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.

Abstracts can be submitted under the following categories:

- HIV (and STI) Prevention in Adolescents
- HIV Prevention in Pregnant and Breastfeeding Persons
- Prevention of Vertical HIV Transmission – Interventions and Implementation
- Clinical Issues in HIV-Exposed Uninfected Children
- Pediatric HIV Case Finding Including Early Infant Diagnosis
- Antiretroviral HIV Treatment in Infants, Children, and Adolescents (Including ARV Switch, Toxicity, Drug Resistance)
- Antiretroviral Treatment Issues in Pregnant and Breastfeeding Persons (Including ARV Switch, Toxicity, Effects on Pregnancy Outcome)
- Clinical Management Issues for Infants, Children, and Pregnant/Breastfeeding Persons (e.g., Monitoring, Differentiated Care)
- Clinical Management Issues Specific to Adolescents (e.g. Transition to Adult Care)
- Coinfections/Complications of HIV/Treatment in Infants, Children, Adolescents, and Pregnant/Breastfeeding Persons
- COVID-19 in Children/Adolescents/Pregnancy and COVID-19 Impacts on HIV Care
Academia from Resource-Limited Settings (RLS) / Early-Career Investigators
We are pleased to waive the registration fee for academia from low-income and lower-middle-income countries and early-career investigators with an accepted abstract. Additionally, a 50% discount on the registration fee will be provided for those without an accepted abstract. The application form is available below.

IMPORTANT: The registration fee is waived for the presenting author only.

To be eligible as an early-career investigator, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;

- Material and Methods: The experimental methods used (including the statistical analyses employed);

- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);

- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 350 words.

Abstracts are considered official communications to the workshop and will be treated confidentially. Submitters of accepted abstracts agree to attend the workshop and present their abstract as scheduled.
Abstract Publication
Accepted abstracts will be published in the Abstract Book : Reviews in Antiviral Therapy & Infectious Diseases. This will be distributed during the workshop and will be available as enduring material after the workshop has concluded. Please note that the workshop secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.

VE and AME is the sole copyright holder of the workshop abstract book as a whole (also referred to as the Reviews in Antiviral Therapy & Infectious Diseases). The abstract authors will retain any and all copyright over their individual abstract. Information on copyright can be viewed in the abstract submission terms and conditions (see 'Terms and Conditions' above).
Oral Presentation Guidelines
- We have allocated 15 minutes for your presentation, of which 1-2 minutes for discussion is included. Chairs have been instructed to strictly adhere to these timelines, therefore, we advise you to rehearse your presentation.
- Please prepare your presentation in PowerPoint
- PC’s will be used for the presentations. If you are working on a MAC computer, you need to format your presentation to a PC-compatible file and check the layout of your presentation before handing it in.
- Avoid too many animations, use common fonts (Arial), readable font size (> 16), and clear colors.
- Submit your presentation on an USB stick (please double-check your USB stick for computer viruses).
- We kindly request that you make your way to the front of the room at least 5 minutes before the start of the session.
Poster Presentation Guidelines
- You are requested to be present by your poster during the poster viewing session.
- The measurements of the poster should not exceed 3ft x 4ft (90 cm x 120 cm) posted in portrait format.
- Please display your abstract number in the upper right corner of your poster.
- Adhesive material for your poster will be provided by the workshop secretariat.
- We would like to ask you to also prepare hand-outs of your poster.
- Your poster should be displayed during both workshop days.
Abstract Submission
Authors can submit their abstracts electronically until 29 April 2022. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Committees
Workshop Chairs 2022
Committee Members

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

We are proud to present the members of the committee:

  • Ellen Chadwick, MD - Ann & Robert H. Lurie Children’s Hospital of Chicago / Northwestern University Feinberg School of Medicine, United States

  • Tsungai Chipato, MBChB - University of Zimbabwe College of Health Sciences, Zimbabwe

  • Polly Clayden - HIV i-Base, United Kingdom

  • Anita De Rossi, PhD - University of Padova / Istituto Oncologico Veneto (IOV)-IRCCS, Italy

  • Marinella Della Negra, MD, PhD - Hospital Emilio Ribas, Brazil

  • Brian Eley, MD - University of Cape Town, South Africa

  • Albert Faye, PhD - Denis Diderot University, Paris, France

  • Rashida Ferrand, MBBS, FRCP, PhD - London School of Hygiene and Tropical Medicine / Biomedical Research and Training Institute, Zimbabwe

  • Pat Flynn, MD - St. Jude Children's Research Hospital, United States

  • Tessa Goetghebuer, MD - Office de la Naissance et de l'Enfance / CHU Saint-Pierree, Belgium

  • Ali Judd, PhD, MRC Clinical Trials Unit, University College London, United Kingdom

  • Valériane Leroy, MD - Inserm, Paris, France

  • Chewe Luo, MD, PhD - UNICEF, United States

  • Dorothy Mbori-Ngacha, MBChB, MMed, MPH - UNICEF, South Africa

  • Sharon Nachman, MD - SUNY Stony Brook / IMPAACT, United States

  • Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, United States

  • Martina Penazzato, MD, MSc, PhD - World Health Organization, Switzerland

  • Ann Petru, MD - UCSF Benioff Children's Hospital Oakland, United States

  • Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Elizabeth Glaser Pediatrics AIDS Foundation / Children’s National Hospital, United States

  • Theodore Ruel, MD - UCSF Benioff Children's Hospital San Francisco, United States

  • George Siberry, MD, MPH, FAAP, FPIDS - United States Agency for International Development (USAID), United States

  • Lynda Stranix-Chibanda, MBChB, MMed - University of Zimbabwe, Zimbabwe

  • Tavitiya Sudjaritruk, MD, ScM, PhD - Chiang Mai University, Thailand

  • Graham Taylor, MD - Imperial College, United Kingdom

  • Claire Thorne, BA, MSc, PhD - University College London, United Kingdom

  • Marissa Vicari - International AIDS Society, Switzerland

  • Rachel Vreeman, MD, MS - Icahn School of Medicine at Mount Sinai, United States

The members of Scientific Committee are hand-picked by the Organizing Committee and the workshop secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

Scholarships

The Scholarship Portal is now closed.

Virology Education (VE), with support from the industry, is offering scholarships to attend HIV & Pediatrics 2022. 

Depending on the type of scholarship awarded, the scholarship covers registration and/or travel and accommodation. 

(The scholarships are supported by industry. These companies will have no control, influence, or involvement in the selection of any attendees.)

What Does the Scholarship Cover?

Registration Scholarship: 

  • Registration only

Partial Scholarship:

  • Registration
  • Accommodation

Full Scholarship:

  • Registration
  • Accommodation
  • Travel
What is Expected from the Scholarship Recipients?

All scholarship awardees are required to attend the full workshop. Awardees must sign in at the beginning of each meeting day and sign off at the end of each day as requested by the Workshop Organizer. At the close of the workshop, awardees must have completed the daily and overall workshop evaluations.

The recipient will provide post-meeting feedback and a summary of his/her/their workshop experience within one month after the end of the workshop. The feedback questionnaire will be an online survey with the recipient providing feedback on their experience at the workshop, scholarship procedure, and how they will implement the knowledge acquired at the meeting in their daily practice. The questionnaire will be sent to each recipient by email within one week after the conclusion of the workshop.

Eligibility

Applicants must:

  • Be proficient in English to interact with faculty and fellow attendees
  • Be actively involved in the field of HIV & Pediatrics 
  • Be able to show benefits to their patients / research / community from attending the workshop
  • Be willing and able to share information learned at the workshop with a larger community
  • Workshop organizer will automatically decline all scholarship applications that do not conform to the eligibility terms
Application Procedure

The scholarship applications must be submitted online through our Scholarship Application Portal by 29 April 2022. The applicant will be asked to submit a motivational letter (max. 200 words) describing how their patients / research / community will benefit from the knowledge gained at this meeting, and their knowledge dissemination strategy, a CV, and a letter of recommendation (optional).

  • All applications will be acknowledged upon receipt.
  • All applications will be reviewed by an independent Scholarship Review Committee.
  • All applicants will be notified about the status of their application in mid-May 2022.
  • Successful applicants will be sent a scholarship agreement.
  • After receipt of the signed scholarship agreement, successful applicants will receive instructions for logistical arrangements.
Selection Criteria

The following criteria will be taken into consideration during the selection process:

  • Professional background
  • Supervisor recommendation
  • Demonstrated benefits to patients / research / community by the knowledge to be gained at this meeting
  • Strategy of knowledge dissemination
  • Early-Career Investigator status 
  • Country of residence
Important
  • Incomplete applications will not be considered. Workshop Organizer cannot be held responsible for any incorrect information that is submitted through the scholarship application portal.
  • Retrospective applications will not be considered.
  • Scholarship recipients must attend the entire workshop.
  • Scholarships are non-transferrable.
  • Workshop Organizer cannot guarantee awarding the scholarship to prospective scholarship recipients until the confirmation of available funds. In the event that sufficient funding for the scholarship is not available, Workshop Organizer will not be liable for any expenses or damages incurred by the prospective scholarship recipient with regards to the scholarship application and/or preparation for the meeting.
  • Applications will be considered until the exhaustion of funds.
  • Scholarship recipients will be responsible for all other costs associated with workshop attendance.
  • Workshop Organizer will not be liable for any injury, death, damage, loss, delay, cost, expense, or inconvenience, causes of action claims and suits for property damage, theft of property or personal injury (including death) arising in connection with the scholarship and participation in the Workshop .
  • Workshop Organizer reserves the right to make the final decision regarding all applications, which cannot be disputed.
Support
Bronze Level
Contributor

Support Our Initiative


Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals and community representatives involved in HIV and pediatrics.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Karin Siebelt at Karin@amededu.com or call +31 30 2307146.
 
Benefits of Support

By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
•    Symposium opportunities
•    Verbal acknowledgment during the program 
•    Discounted and complimentary registrations for your representatives
•    Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, program book, the streaming platform, and our website
•    Digital and printed advertising opportunities 
•    Social media shout-outs
•    Logo on the digital conference bag 
 
*Subject to the support level

Endorsers
Photo Gallery
Group Photo
Media
Invitation to Join the International Workshop on HIV & Pediatrics | 27-28 July 2022

Fatima Kakkar, MD, MPH, FRCPC
CHU Sainte-Justine / Université de Montréal, Canada

Jason Brophy, MD, MSc, DTM, FRCPC
Children's Hospital of Eastern Ontario, Canada

Previous Editions
COVID-19

Health & Safety Measures regarding COVID-19

Ensuring the health and safety of our attendees, suppliers, and staff is our absolute number one priority. In order to provide a safe conference environment, all hybrid and live events organized by Virology Education will follow the national health and safety measures of the country where the meeting is being held in. We kindly ask that all attendees carefully abide by these measures to assist us in ensuring a safe environment for all.

National Health & Safety Measures

The health and safety measures that will be taken by Virology Education during the International Workshop on HIV & Pediatrics are listed on the government website of Canada. Please read them very carefully before travelling to the conference venue.

Our staff will be available onsite to address any questions or concerns that you might have. If you have any questions in advance, please contact the Conference Secretariat at christina.moustakaki@amededu.com

Travelling to Canada

Virology Education strongly advises participants to check the government website of Canada for the latest and most accurate information about the rules regarding travel.

Please be aware of measures such as testing requirements, vaccination requirements, whether your country of origin is mentioned on the Red List, etc. 

What if I get ill during the event?

Should an attendee become ill or exhibit COVID-19 symptoms at any time during the event, the attendee will safely withdraw from the event venue and immediately notify the event organizer with details of other attendees which have been in close contact at the event. By registering for the event, the attendee declares, acknowledges, and accepts that they will comply with all local government requirements should they become ill or exhibit COVID-19 symptoms during the event.

Liability Waiver
Virology Education cannot guarantee that its participants, volunteers, partners, or others in attendance will not become infected with COVID-19.
To the maximum extent permitted by law, Virology Education accepts no liability for any illness, COVID-19 related or otherwise, that may subsequently be contracted after or during the event.
All participants acknowledge and agree that they are attending the event at their own risk.

Language
Ratings previous edition
Content is relevant to my practice
4.4
(60)
Content was free from commercial bias
4.5
Overall event experience
4.9